Want to see AU:LDX full AI Analyst Report?
LDX Stock Chart & Stats
AU$0.32
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.32
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.08 - AU$0.33
Previous CloseN/A
Volume213.94K
Average Volume (3M)963.98K
Market Cap
AU$82.02M
Enterprise ValueAU$85.46M
Total Cash (Recent Filing)AU$15.42M
Total Debt (Recent Filing)AU$5.94M
Price to Earnings (P/E)―
Beta2.08
Next Earnings
Mar 04, 2027Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding988,166,260
10 Day Avg. Volume1,139,239
30 Day Avg. Volume963,977
Financial Highlights & Ratios
PEG Ratio0.28
Price to Book (P/B)2.59
Price to Sales (P/S)4.38
P/FCF Ratio-37.94
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.25Price Target Upside-21.88% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.02
Revenue Forecast (FY)AU$30.93M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSteady revenue growth indicates improving commercial traction for Lumos’s rapid point-of-care diagnostics. If sustained, expanding sales can support greater operating scale, strengthen market presence, and provide a foundation for improving profitability as the company commercializes more products.
Improved Operating Cash FlowThe move to positive operating cash flow is a constructive sign that working-capital control or cost discipline has improved. Maintaining this progress would reduce reliance on external funding for routine operations and demonstrate stronger underlying cash conversion over the coming quarters.
Manageable Absolute DebtModerate absolute debt and positive reported equity provide Lumos with a more stable balance-sheet base than an insolvent structure. This can preserve some flexibility to continue product development and commercialization, provided losses do not continue eroding equity materially.
Bears Say
Persistent LossesRecurring operating and net losses show that revenue growth has not yet translated into a sustainable earnings model. Continued losses can consume equity, limit internally funded investment, and increase dependence on financing while management works to reach commercial profitability.
Negative Gross ProfitA negative gross profit is a significant deterioration in the economics of products or services before operating expenses are considered. Unless reversed, it can prevent revenue growth from improving earnings and may require pricing, product-mix, or cost changes to restore durable margins.
Negative Free Cash FlowNegative free cash flow means operating activity is not yet sufficient to cover investment and other cash requirements. Even with positive operating cash flow, ongoing cash deficits can raise funding needs, constrain development spending, and make the business less resilient if losses persist.
Lumos Diagnostics Holdings Ltd. News
LDX FAQ
What was Lumos Diagnostics Holdings Ltd.’s price range in the past 12 months?
Lumos Diagnostics Holdings Ltd. lowest share price was AU$0.08 and its highest was AU$0.33 in the past 12 months.
What is Lumos Diagnostics Holdings Ltd.’s market cap?
Lumos Diagnostics Holdings Ltd.’s market cap is AU$82.02M.
When is Lumos Diagnostics Holdings Ltd.’s upcoming earnings report date?
Lumos Diagnostics Holdings Ltd.’s upcoming earnings report date is Mar 04, 2027 which is in 129 days.
How were Lumos Diagnostics Holdings Ltd.’s earnings last quarter?
Lumos Diagnostics Holdings Ltd. released its earnings results on Aug 25, 2026. The company reported AU$0 earnings per share for the quarter, beating the consensus estimate of -AU$0.014 by AU$0.014.
Is Lumos Diagnostics Holdings Ltd. overvalued?
According to Wall Street analysts Lumos Diagnostics Holdings Ltd.’s price is currently Overvalued.
Does Lumos Diagnostics Holdings Ltd. pay dividends?
Lumos Diagnostics Holdings Ltd. does not currently pay dividends.
What is Lumos Diagnostics Holdings Ltd.’s EPS estimate?
Lumos Diagnostics Holdings Ltd.’s EPS estimate is 0.
How many shares outstanding does Lumos Diagnostics Holdings Ltd. have?
Lumos Diagnostics Holdings Ltd. has 988,166,260 shares outstanding.
What happened to Lumos Diagnostics Holdings Ltd.’s price movement after its last earnings report?
Lumos Diagnostics Holdings Ltd. reported an EPS of AU$0 in its last earnings report, beating expectations of -AU$0.014. Following the earnings report the stock price went up 5%.
Which hedge fund is a major shareholder of Lumos Diagnostics Holdings Ltd.?
Currently, no hedge funds are holding shares in AU:LDX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Lumos Diagnostics Holdings Ltd. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$0.25 (-21.88% Downside)
AU$0.25 (-21.88% Downside)
Blogger Sentiment
Bullish
AU:LDX Sentiment 91%
Sector Average 67%
Sector Average 67%
Insider Transactions
Bought Shares
Worth AU$21.2K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-66.12%
12-Months-Change
Fundamentals
Return on Equity
-35.89%
Trailing 12-Months
Asset Growth
85.23%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Lumos Diagnostics Holdings Ltd.
Lumos Diagnostics Holdings Limited develops, manufactures, and commercializes point-of-care diagnostic products for diagnosis and management of infectious diseases in the United States. The company’s products include FebriDx, a point-of-care diagnostic test for detecting and differentiating viral and bacterial respiratory infections; and ViraDx, a three-in-one point-of-care test for influenza A, influenza B, and COVID-19. It also provides assay development and manufacturing services for point-of-care tests and proprietary digital reader platforms. Lumos Diagnostics Holdings Limited was incorporated in 2018 and is based in Carlsbad, California.
LDX Stock 12 Month Forecast
Average Price Target
AU$0.25
▼(-21.88% Downside)
Technical Analysis
Genetic Technologies
―
BCAL Diagnostics Limited
―
Genetic Signatures Ltd.
―
Sonic Healthcare Limited
―
Australian Clinical Labs Ltd
―






